The verdict
Tesamorelin fits a man whose main problem is deep abdominal fat that has not moved with diet and training, and who wants the peptide with the stronger trial record for that specific target. Sermorelin fits a man looking for a gentler nudge to his own growth hormone rhythm, often for sleep quality and recovery, who accepts that the evidence is older and smaller.
Neither is a weight-loss drug, and neither replaces the basics. Both work better alongside training, adequate protein and good sleep, and both need IGF-1 checks along the way.
Side-by-side comparison
| Tesamorelin | Sermorelin | |
|---|---|---|
| What it is | Stabilized analog of the full 44-amino-acid growth hormone releasing hormone | The first 29 amino acids of growth hormone releasing hormone |
| FDA status | Approved as Egrifta for excess abdominal fat in adults with HIV lipodystrophy; other use is off-label | Previously approved as Geref, withdrawn by the maker; now available as a compounded preparation |
| Main evidence | Randomized trials showing visceral fat reduction | Small, older studies in older adults and children |
| Typical goal at a men’s clinic | Visceral fat and body composition | Sleep, recovery, general support |
| How it is taken | Daily injection under the skin of the abdomen | Usually a nightly injection under the skin |
| Monitoring | IGF-1, glucose and A1C, lipids | IGF-1 and metabolic markers |
| Cost drivers | Brand versus compounded supply, dose, length of use | Compounded supply, dose, length of use |
How each one works
Both peptides mimic growth hormone releasing hormone, the signal your hypothalamus sends to the pituitary. The pituitary responds by releasing your own growth hormone in pulses, and the liver turns that into IGF-1, the marker labs use to track the effect. Because the body’s own feedback stays in place, the rise is more limited than injecting growth hormone directly.
Tesamorelin is the full-length hormone with a modification that helps it last longer in the body. Sermorelin is the shorter active fragment and is cleared more quickly. Our page on growth hormone decline in men explains why levels fall with age and what that does and does not mean.
What the evidence shows
Tesamorelin has the stronger record. In a 26-week trial of 412 people with HIV, 86% of them men, visceral fat measured by CT fell 15.2% on tesamorelin and rose 5.0% on placebo, triglycerides dropped, and IGF-1 rose 81%. Outside HIV, a 12-month trial in 60 adults with abdominal obesity and reduced growth hormone secretion found visceral fat fell by 16 square centimeters on tesamorelin while it rose by 19 on placebo, with no change in fasting glucose or A1C.
Sermorelin’s history is longer but thinner. Geref was approved in 1990 and 1997, and in 2013 the FDA determined it had not been withdrawn for reasons of safety or effectiveness. The closest study to today’s use gave older men and women a nightly GHRH(1-29) analog for 16 weeks: IGF-1 rose, and men gained lean mass and reported better well-being and libido, but sleep quality did not change. Men often report sleeping better on sermorelin, and that experience is real to them, but the trial data do not yet confirm it.
No trial has compared the two peptides head to head, so any claim that one is stronger rests on separate studies in different groups of people. What the record does support is narrower: tesamorelin reliably reduces visceral fat in the populations studied, and both peptides raise IGF-1. Everything beyond that should be judged on your own labs and measurements over the first few months.
Side effects and who should not use them
The Egrifta WR label lists joint pain, injection-site redness and itching, limb pain, swelling in the legs and muscle aches as the most common effects. It asks for a glucose check before starting, because diabetes was more frequent than on placebo in trials, and for IGF-1 monitoring, with a stop if levels stay too high. Fluid retention can cause swelling or carpal tunnel symptoms. It is not used with active cancer or a disrupted pituitary axis.
Sermorelin’s side effect data are older and sparser. In the 16-week study above, the only adverse effect reported was a temporary rise in blood lipids. The same screening applies to both: no active or recent cancer, no untreated pituitary disease, and lab follow-up rather than open-ended use. Our page on IGF-1 on sermorelin or tesamorelin explains the targets.
Cost and convenience
Both are small injections given with an insulin-type needle, tesamorelin daily and sermorelin usually at bedtime. The Egrifta WR label notes that one vial, once mixed, supplies seven daily doses, and that the newer version is not interchangeable with Egrifta SV.
Cost depends mostly on whether a brand or a compounded preparation is used, the dose, how long you stay on it and how often IGF-1 and other labs are repeated. We do not list prices here; the tesamorelin cost and sermorelin cost pages walk through each driver so you can compare quotes. If visceral fat is the target, also read tesamorelin vs GLP-1 for visceral fat.
How Ultimate Male helps you choose
At Ultimate Male, a growth hormone peptide is never the first step. After a free 10-minute call, you get on-site labs including IGF-1, metabolic and hormone markers, then a one-on-one consultation with a PA-C or MD about whether a peptide fits at all, and which one. Your peptide comes from a licensed U.S. compounding pharmacy, and the first injection is shown to you in clinic.
Follow-up labs and a check-in at six to eight weeks decide whether to continue, adjust or stop. The provider will also tell you plainly where each product stands with the FDA. Compare the details on the tesamorelin and sermorelin pages, or start with the peptide therapy overview.
